Ruled, but not ruined, by migraine

Audrey Craven knows the isolation migraine can cause. When her migraines were at their worst, Audrey Craven vowed to use her experience to help others navigate their migraine journey and feel less alone.

Read Story

This is Lundbeck

We are one of the only biopharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our Science

LATEST NEWS

18 October, 2023 Feature
Majority of Canadians on Public Drug Plans Now Eligible for Coverage of Vyepti® (eptinezumab) for the Prevention of Migraine
03 March, 2021 Feature
Health Canada Approves Otsuka and Lundbeck’s ABILIFY MAINTENA® (aripiprazole for prolonged release injectable suspension) Alternative Initiation Regimen
09 February, 2021 Feature
'Montréal's Top Employers' for 2021 Announced

See All News

Come join us in making a difference to patients worldwide.

Job Opportunities

Explore the latest financial developments at Lundbeck.

Investors

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease.

Patients

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.